Results 1 to 10 of about 24 (18)

Efficacy of divozilimab in the treatment of systemic sclerosis: results of the randomized phase III clinical trial BCD-132-5/LIBERIUS [PDF]

Современная ревматология
The search for new therapeutic options for the treatment of systemic sclerosis (SSc) is an urgent issue in rheumatology. The article presents the results of the double-blind, randomized, placebo-controlled phase III clinical trial BCD-132-5/LIBERIUS on ...
L. P. Ananyeva, M. N. Starovoytova, I. Z. Gaydukova, G. V. Lukina, E. V. Zonova, L. V. Eliseeva, G. F. Fatkhullina, D. I. Abdulganieva, D. G. Krechikova, T. V. Kropotina, O. B. Nesmeyanova, I. B. Vinogradova, E. S. Zhugrova, L. V. Ivanova, N. E. Nikulenkova, O. R. Ziganshin, T. V. Plaksina, M. V. Zlobin, Yu. Yu. Grabovetskaya, N. F. Soroka, O. B. Ershova, T. V. Povarova, O. N. Anoshenkova, A. A. Lutsky, A. V. Zinkina-Orikhan, Yu. N. Linkova, E. A. Fokina, A. A. Porozova, A. V. Eremeeva   +28 more
doaj   +4 more sources

Antibodies to watch in 2024. [PDF]

MAbs
The ‘Antibodies to Watch’ article series provides an annual summary of commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical development, regulatory review, and those recently granted a first approval in any country. In
Crescioli S, Kaplon H, Chenoweth A, Wang L, Visweswaraiah J, Reichert JM.   +5 more
europepmc   +3 more sources

Targeted therapy of multiple sclerosis: real-world experience with divozilimab

Анналы клинической и экспериментальной неврологии
Introduction. Anti-B-cell therapy that prevents clonal expansion of B cells expressing CD20 is a significant achievement in the pharmacotherapy of multiple sclerosis (MS).
Daria D. Eliseeva, Ekaterina V. Baydina, Taras O. Simaniv, Lola Sh. Askarova, Julia E. Korzhova, Inessa V. Zakroyshchikova, Ivan A. Kochergin, Oksana E. Panova, Ekaterina O. Chekanova, Denis V. Shevchuk, Aleksandra O. Kozlova, Dmitry A. Ganin, Kirill V. Sapozhnikov, Mariya N. Zakharova   +13 more
doaj   +2 more sources

The efficacy and safety of divozilimab in patient with systemic sclerosis: 48-week results of the randomized double-blind placebo-controlled phase III clinical study LIBERIUS

Научно-практическая ревматология
The aim of the study is to evaluate the efficacy, safety and immunogenicity of divozilimab (DIV), anti-CD20 monoclonal antibody, in patients with systemic sclerosis (SS).Materials and methods.
L. P. Ananyeva, M. N. Starovoytova, I. Z. Gaydukova, G. V. Lukina, E. V. Zonova, L. V. Eliseeva, G. F. Fatkhullina, D. I. Abdulganieva, D. G. Krechikova, T. V. Kropotina, O. B. Nesmeyanova, I. B. Vinogradova, E. S. Zhugrova, L. V. Ivanova, N. E. Nikulenkova, O. R. Ziganshin, T. V. Plaksina, M. V. Zlobin, Yu. Yu. Grabovetskaya, N. F. Soroka, O. B. Ershova, T. V. Povarova, O. N. Anoshenkova, A. A. Lutckii, A. V. Zinkina-Orikhan, Yu. N. Linkova, E. A. Fokina, A. A. Porozova, P. S. Pukhtinskaia, A. V. Eremeeva   +29 more
doaj   +2 more sources

Russian-Belarusian Expert Council “New opportunities in the treatment of patients with multiple sclerosis” (October 1, 2023). Main conclusions of the first meeting

Неврология, нейропсихиатрия, психосоматика, 2023
A joint conclusion of the Russian-Belarusian Expert Council “New opportunities in the treatment of patients with multiple sclerosis” on the organization of medical care, diagnosis and treatment of multiple sclerosis (MS) and other autoimmune diseases is ...
A. N. Boyko, V. V. Vashchilin, O. V. Boyko, A. G. Bunyak, D. S. Kasatkin, D. S. Korobko, S. I. Kulikova, N. V. Mazgo, N. V. Makovskaya, S. A. Sivertseva, I. V. Smagina, T. N. Chernukha   +11 more
doaj   +1 more source

Divozilimab reduces the risk of exacerbations in patients with neuromyelitis optica spectrum disorders

Neurology, Neuropsychiatry, Psychosomatics
Objective: the aim of the AQUARELLE trial was to evaluate the efficacy of divozilimab compared with a historical control (placebo) and to characterise its safety in patients with neuromyelitis optica spectrum disorder (NMOSD).Material and methods. The AQUARELLE clinical trial population included patients aged 18 years and older with a diagnosis of ...
A. N. Boyko, M. N. Zakharova, T. O. Simaniv, V. M. Alifirova, E. G. Arefieva, M. A. Barabanova, Z. A. Goncharova, I. V. Greshnova, N. V. Dorogov, V. A. Dudin, D. S. Korobko, S. V. Kotov, G. N. Mishin, E. V. Parshin, I. E. Poverennova, D. V. Pokhabov, V. M. Lebedev, I. V. Smagina, N. N. Spirin, S. A. Sivertseva, N. A. Totolyan, D. F. Khairutdinova, T. N. Trushnikova, L. G. Zaslavsky, K. Z. Bakhtiyarova, E. V. Prazdnichkova, F. A. Khabirov, A. G. Bunyak, R. E. Yakubtsevich, D. G. Tolkacheva, K. V. Sapozhnikov, O. N. Mironenko, A. A. Lazarev, V. D. Batorova, M. V. Krasnova, A. A. Porozova, A. V. Eremeeva, Yu. N. Linkova, A. V. Zinkina-Orikhan   +38 more
openaire   +1 more source

Delving into Molecular Pathways: Analyzing the Mechanisms of Action of Monoclonal Antibodies Integrated in IMGT/mAb-DB for Myasthenia Gravis. [PDF]

Vaccines (Basel), 2023
Golfinopoulou R, Giudicelli V, Manso T, Kossida S.   +3 more
europepmc   +1 more source

Enhancing Antibody Exposure in the Central Nervous System: Mechanisms of Uptake, Clearance, and Strategies for Improved Brain Delivery. [PDF]

J Nanotheranostics, 2023
Schwinghamer K, Siahaan TJ.
europepmc   +1 more source

The B-cells paradigm in systemic sclerosis: an update on pathophysiology and B-cell-targeted therapies. [PDF]

Clin Exp Immunol
Scaletti C, Pratesi S, Bellando Randone S, Di Pietro L, Campochiaro C, Annunziato F, Matucci Cerinic M.   +6 more
europepmc   +1 more source

Clinical, mechanistic, and therapeutic landscape of cutaneous fibrosis. [PDF]

Sci Transl Med
Li DJ, Berry CE, Wan DC, Longaker MT.
europepmc   +1 more source